Evidence map›Paper›PMID 40850616›Full record

ArticleJournal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer2026

MTAP Expression by Immunohistochemistry: A Novel Biomarker in NSCLC.

Magdalena M Brune, Luca Roma, Obinna Chijioke, Ilaria Alborelli, Martin Zacharias, Lenard Bubendorf, Tatjana Vlajnic, Nikolaus Deigendesch, Julian Pollinger, Petra Hirschmann and 4 more

Abstract read
PubMed Publisher
In one paragraph

Article in Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Article
  2. Article
  3. Prevalence and Actionability of MTAP Loss in Oncogene-Driven Lung Cancer.bioRxiv : the preprint server for biology · 2026
    Article
  4. Review
  5. International journal of molecular sciences · 2025
    Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

14 authors.

Magdalena M BrunePathology, Institute of Medical Genetics and Pathology, University Hospital Basel, University of Basel, Basel, Switzerland.
Luca RomaPathology, Institute of Medical Genetics and Pathology, University Hospital Basel, University of Basel, Basel, Switzerland.
Obinna ChijiokePathology, Institute of Medical Genetics and Pathology, University Hospital Basel, University of Basel, Basel, Switzerland.
Ilaria AlborelliPathology, Institute of Medical Genetics and Pathology, University Hospital Basel, University of Basel, Basel, Switzerland.
Martin ZachariasDiagnostic and Research Institute of Pathology, Medical University of Graz, Graz, Austria.
Lenard BubendorfPathology, Institute of Medical Genetics and Pathology, University Hospital Basel, University of Basel, Basel, Switzerland.
Tatjana VlajnicPathology, Institute of Medical Genetics and Pathology, University Hospital Basel, University of Basel, Basel, Switzerland.
Nikolaus DeigendeschPathology, Institute of Medical Genetics and Pathology, University Hospital Basel, University of Basel, Basel, Switzerland.
Julian PollingerPathology, Institute of Medical Genetics and Pathology, University Hospital Basel, University of Basel, Basel, Switzerland.
Petra HirschmannPathology, Institute of Medical Genetics and Pathology, University Hospital Basel, University of Basel, Basel, Switzerland.
David KönigDivision of Medical Oncology, University Hospital Basel, Basel, Switzerland.
Sebastian OttDepartment of Pulmonology and Thoracic Surgery, St. Clara Hospital, Basel, Switzerland and University of Bern, Bern, Switzerland.
Spasenija Savic-PrincePathology, Institute of Medical Genetics and Pathology, University Hospital Basel, University of Basel, Basel, Switzerland.
Lukas BubendorfPathology, Institute of Medical Genetics and Pathology, University Hospital Basel, University of Basel, Basel, Switzerland. Electronic address: lukas.bubendorf@usb.ch.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionLoss of MTAP serves as a potential predictive marker of response to cooperative PRMT5 inhibitors and as a negative predictor of response to immune checkpoint inhibitors. We investigated the prevalence of MTAP deficiency by immunohistochemistry (IHC) in NSCLC as a surrogate for MTAP loss.

methodsMTAP IHC was performed on 698 NSCLC samples. Data from routine next-generation sequencing, analyzed with the Oncomine Precision Assay (OPA-NGS, Thermo Fisher), were available in 426 cases, including CDKN2A copy number variation (CNV) data in 411 cases. Our findings were compared with data from The Cancer Genome Atlas (TCGA).

resultsMTAP deficiency by IHC was found in 18.2% of NSCLC. CDKN2A loss by OPA-NGS, used as a surrogate for MTAP loss, was significantly associated with MTAP deficiency by IHC, but it was found in only 28.4% of the MTAP-deficient NSCLC analyzed for CDKN2A CNV. In the TCGA cohort, only 72.9% of NSCLC with CDKN2A loss had a concurrent MTAP loss defined by CNV.

conclusionMTAP IHC seems to be better suited than OPA-NGS to assess the MTAP status in NSCLC, especially as the MTAP gene is not specifically covered within this panel. CDKN2A loss is not a reliable MTAP loss surrogate, as it overestimates MTAP loss in more than 25% of the cases in the TCGA cohort.

Indexed as

Biomarkers, TumorCarcinoma, Non-Small-Cell LungLung NeoplasmsPurine-Nucleoside PhosphorylaseAgedFemaleHumansImmunohistochemistryMaleMiddle AgedPrognosis5'-methylthioadenosine phosphorylaseBiomarkers, TumorPurine-Nucleoside PhosphorylaseImmunohistochemistryMTAPNext generation sequencingNSCLC

Identifiers

PMID40850616

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.